Stephen V Liu, Director of Thoracic Oncology, Chief of the Division of Hematology and Oncology, and Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared a post on shared a post on X:
“Subset data from ALINA – adjuvant alectinib for resected ALK+ NSCLC – shows benefit to alectinib over chemo across subsets – stage, size, N0/N1/N2, and time from surgery. Current standard of care.”
Title: Disease characteristics and treatment outcomes in patients with resected early-stage ALK-positive non-small cell lung cancer from the randomized ALINA trial
Authors: Fabrice Barlesi, Jin Seok Ahn, Benjamin J. Solomon, Makoto Nishio, Rafal Dziadziuszko, Dae Ho Lee, Jong-Seok Lee, Wenzhao Zhong, Hidehito Horinouchi, Weimin Mao, Maximilian Hochmair, Filippo de Marinis, Maria Rita Migliorino, Igor Bondarenko, Tingting Xu, Ilze Bara, Beiying Ding, Celina Ngiam, Patricia Petric, Yi-Long Wu
Other Articles about ALINA trial on OncoDaily.